Clinical impact of adopting an AI-driven opportunistic bone health screening software using routine X-ray.

Catriona Aileen Syme¹, Melanie Lopes¹, Alexander Bilbily^1,2, Mark D Cicero^3,4,5

¹16 Bit Inc., 20 Bay Street, 11Th Floor, Toronto, ON, M5J 2N8, Canada.

²Sunnybrook Health Sciences, University of Toronto, Toronto, ON, Canada.

³16 Bit Inc., 20 Bay Street, 11Th Floor, Toronto, ON, M5J 2N8, Canada. mark@16Bit.ai.

⁴True North Imaging, Toronto, ON, Canada. mark@16Bit.ai.

⁵Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada. mark@16Bit.ai.

PubMed DOI

Abstract

OBJECTIVES: To evaluate the clinical impact of an artificial intelligence device, Rho, that opportunistically screens X-rays for low bone mineral density (BMD; DXA T-score < -1). MATERIALS AND METHODS: Over 13 months, Rho analyzed X-rays from patients ≥ 50 years at a large independent health facility. Radiologists could opt to include Rho-flagged findings in their X-ray reports. DXAs that occurre…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.